Parkinson’s Disease: Physiopathologic and Therapeutic Aspects
Autor(a) principal: | |
---|---|
Data de Publicação: | 2010 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Saúde e Pesquisa (Online) |
Texto Completo: | https://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/1353 |
Resumo: | The Parkinson’s Disease (PD) is one of the most frequent degenerative affections of the central nervous system, of progressive character, that attacks base nuclei. Clinically, it is characterized by rest tremor, muscular rigidity and bradicinesia. With the progression of the disease, the patient has gradual limitation on that independence with damages for his autonomy. The physical-mental, emotional, social and economical issues associated to the signs and symptoms and to the secondary complications of PD interfere in the individual's incapacity level and can negatively influence his quality of life. The levodopa is the metabolic precursor of the dopamine and separately the most effective drug for the treatment of PD. Practically, the use of this drug is associated with Carbidopa or Benserazide, because while administered separately it is largely decarboxilated. Its use relieves some of the symptoms related to the motor part of PD. The bibliographical research was carried out on index sites and some books regarding the subject. This review makes it clearer that the evolution of the disease is variable, because the patients can be little disabled and spend many years with the same symptoms while the progression in other patients is faster. What we should keep clear is that, with the available therapeutic resources, in most of the cases, it is possible to maintain the patient in clinical conditions that allow him, for long periods, to live a normal life, or close to this, although a radical, definitive cure is still not possible. |
id |
CESUMAR-1_ee1e2fa621d1b7ed0f046fff7e663ecd |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/1353 |
network_acronym_str |
CESUMAR-1 |
network_name_str |
Saúde e Pesquisa (Online) |
repository_id_str |
|
spelling |
Parkinson’s Disease: Physiopathologic and Therapeutic AspectsDoença de Parkinson: Aspectos Fisiopatológicos e TerapêuticosAntiparkinsonianParkinson's diseaseLevodopa.AntiparkinsonianosDoença de ParkinsonLevodopa.The Parkinson’s Disease (PD) is one of the most frequent degenerative affections of the central nervous system, of progressive character, that attacks base nuclei. Clinically, it is characterized by rest tremor, muscular rigidity and bradicinesia. With the progression of the disease, the patient has gradual limitation on that independence with damages for his autonomy. The physical-mental, emotional, social and economical issues associated to the signs and symptoms and to the secondary complications of PD interfere in the individual's incapacity level and can negatively influence his quality of life. The levodopa is the metabolic precursor of the dopamine and separately the most effective drug for the treatment of PD. Practically, the use of this drug is associated with Carbidopa or Benserazide, because while administered separately it is largely decarboxilated. Its use relieves some of the symptoms related to the motor part of PD. The bibliographical research was carried out on index sites and some books regarding the subject. This review makes it clearer that the evolution of the disease is variable, because the patients can be little disabled and spend many years with the same symptoms while the progression in other patients is faster. What we should keep clear is that, with the available therapeutic resources, in most of the cases, it is possible to maintain the patient in clinical conditions that allow him, for long periods, to live a normal life, or close to this, although a radical, definitive cure is still not possible.A Doença de Parkinson (DP) é uma das afecções degenerativas do sistema nervoso central mais frequentes, de caráter progressivo, que acomete núcleos de base. Clinicamente, caracteriza-se por tremor de repouso, rigidez muscular e bradicinesia. Com a progressão da doença, o paciente tem limitação gradativa dessa independência com prejuízos para sua autonomia. Os comprometimentos físico-mental, emocional, social e econômico associados aos sinais e sintomas e às complicações secundárias da DP interferem no nível de incapacidade do indivíduo e podem influenciar negativamente a qualidade de vida do mesmo. A levodopa é o precursor metabólico da dopamina e isoladamente o fármaco mais eficaz para o tratamento da DP. Na prática, o uso deste fármaco é associado à Carbidopa ou Benserazida, pois administrada isoladamente ela é em grande parte descarboxilada. O uso da desta alivia alguns dos sintomas relacionados à parte motora da DP. A pesquisa bibliográfica foi realizada em sites indexadores e alguns livros referente ao assunto. A presente revisão torna mais claro que a evolução da doença é variável, pois os pacientes podem permanecer muitos anos com os mesmo sintomas e pouco incapacitados ao lado de outros cuja progressão é mais rápida. O que se deve manter claro é que, com os recursos terapêuticos disponíveis, na maioria dos casos, é possível manter o paciente em condições clínicas que permitam, por longos períodos, um nível de vida normal ou próximo a este, embora uma cura radical, definitiva, ainda não seja possível.Universidade Cesumar - UniCesumar2010-05-18info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionRevisão de Literaturaapplication/pdfhttps://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/1353Saúde e Pesquisa; Vol 3 No 2 (2010): maio/ago.Saúde e Pesquisa; v. 3 n. 2 (2010): maio/ago.2176-9206reponame:Saúde e Pesquisa (Online)instname:Cesumar Diretoria de Pesquisainstacron:CESUMARporhttps://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/1353/1080Ferreira, Flavio DiasFerreira, Francine Maery DiasHeleno, Raquel BalestriMella Júnior, Sidney Edsoninfo:eu-repo/semantics/openAccess2022-05-23T16:28:11Zoai:ojs.pkp.sfu.ca:article/1353Revistahttps://periodicos.unicesumar.edu.br/index.php/saudpesqPUBhttps://periodicos.unicesumar.edu.br/index.php/saudpesq/oainaep@cesumar.br2176-92061983-1870opendoar:2022-05-23T16:28:11Saúde e Pesquisa (Online) - Cesumar Diretoria de Pesquisafalse |
dc.title.none.fl_str_mv |
Parkinson’s Disease: Physiopathologic and Therapeutic Aspects Doença de Parkinson: Aspectos Fisiopatológicos e Terapêuticos |
title |
Parkinson’s Disease: Physiopathologic and Therapeutic Aspects |
spellingShingle |
Parkinson’s Disease: Physiopathologic and Therapeutic Aspects Ferreira, Flavio Dias Antiparkinsonian Parkinson's disease Levodopa. Antiparkinsonianos Doença de Parkinson Levodopa. |
title_short |
Parkinson’s Disease: Physiopathologic and Therapeutic Aspects |
title_full |
Parkinson’s Disease: Physiopathologic and Therapeutic Aspects |
title_fullStr |
Parkinson’s Disease: Physiopathologic and Therapeutic Aspects |
title_full_unstemmed |
Parkinson’s Disease: Physiopathologic and Therapeutic Aspects |
title_sort |
Parkinson’s Disease: Physiopathologic and Therapeutic Aspects |
author |
Ferreira, Flavio Dias |
author_facet |
Ferreira, Flavio Dias Ferreira, Francine Maery Dias Heleno, Raquel Balestri Mella Júnior, Sidney Edson |
author_role |
author |
author2 |
Ferreira, Francine Maery Dias Heleno, Raquel Balestri Mella Júnior, Sidney Edson |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Ferreira, Flavio Dias Ferreira, Francine Maery Dias Heleno, Raquel Balestri Mella Júnior, Sidney Edson |
dc.subject.por.fl_str_mv |
Antiparkinsonian Parkinson's disease Levodopa. Antiparkinsonianos Doença de Parkinson Levodopa. |
topic |
Antiparkinsonian Parkinson's disease Levodopa. Antiparkinsonianos Doença de Parkinson Levodopa. |
description |
The Parkinson’s Disease (PD) is one of the most frequent degenerative affections of the central nervous system, of progressive character, that attacks base nuclei. Clinically, it is characterized by rest tremor, muscular rigidity and bradicinesia. With the progression of the disease, the patient has gradual limitation on that independence with damages for his autonomy. The physical-mental, emotional, social and economical issues associated to the signs and symptoms and to the secondary complications of PD interfere in the individual's incapacity level and can negatively influence his quality of life. The levodopa is the metabolic precursor of the dopamine and separately the most effective drug for the treatment of PD. Practically, the use of this drug is associated with Carbidopa or Benserazide, because while administered separately it is largely decarboxilated. Its use relieves some of the symptoms related to the motor part of PD. The bibliographical research was carried out on index sites and some books regarding the subject. This review makes it clearer that the evolution of the disease is variable, because the patients can be little disabled and spend many years with the same symptoms while the progression in other patients is faster. What we should keep clear is that, with the available therapeutic resources, in most of the cases, it is possible to maintain the patient in clinical conditions that allow him, for long periods, to live a normal life, or close to this, although a radical, definitive cure is still not possible. |
publishDate |
2010 |
dc.date.none.fl_str_mv |
2010-05-18 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Revisão de Literatura |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/1353 |
url |
https://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/1353 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/1353/1080 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Cesumar - UniCesumar |
publisher.none.fl_str_mv |
Universidade Cesumar - UniCesumar |
dc.source.none.fl_str_mv |
Saúde e Pesquisa; Vol 3 No 2 (2010): maio/ago. Saúde e Pesquisa; v. 3 n. 2 (2010): maio/ago. 2176-9206 reponame:Saúde e Pesquisa (Online) instname:Cesumar Diretoria de Pesquisa instacron:CESUMAR |
instname_str |
Cesumar Diretoria de Pesquisa |
instacron_str |
CESUMAR |
institution |
CESUMAR |
reponame_str |
Saúde e Pesquisa (Online) |
collection |
Saúde e Pesquisa (Online) |
repository.name.fl_str_mv |
Saúde e Pesquisa (Online) - Cesumar Diretoria de Pesquisa |
repository.mail.fl_str_mv |
naep@cesumar.br |
_version_ |
1754122531983327232 |